Abstract
Background: Lung cancer is the most commonly diagnosed cancer worldwide. 87% of cases are classified as NSCLC. NF1 is a tumour suppressor gene which limits RAS mediated signal transduction within the MAPK pathway. Up-regulation of this pathway leads to uncontrolled cellular proliferation. Somatic mutations in NF1 are reported in 8–12% of NSCLC patients. We hypothesise that NF1 variants have a functional consequence on the activation of the MAPK pathway.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
